glp 1 receptor agonist moa Glucagon-like peptide-1 Video: Non-insulin injectable antidiabetic drugs

For example, in the SUSTAIN 5 clinical trial, patients with HbA1c levels of 8.0% or lower had their basal insulin doses reduced by 20% when starting semaglutide therapy to minimize the risk of low blood sugar

According to Sinha et al., tirzepatide has better efficacy compared to many glucose-lowering medications such as dulaglutide, glargine, semaglutide, and insulin degludec and placebo drugs [14]

[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Rode AKO, et al

Recuperato da: Bornebusch AB, Fink-Jensen A, Wrtwein G, Seeley RJ, Thomsen M

[6] Tirzepatide (Mounjaro): up to 15 mg once weekly for type 2 diabetes, and up to 15 mg once weekly for chronic weight management (marketed as Tirzepatide)

After removal of duplicates, 290 unique records remained for title and abstract screening